

# Gianfranco Delle Fave

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10644647/publications.pdf>

Version: 2024-02-01

88  
papers

8,082  
citations

70961

41  
h-index

51492

86  
g-index

88  
all docs

88  
docs citations

88  
times ranked

7750  
citing authors

#	ARTICLE	IF	CITATIONS
1	Morphological Factors Related to Nodal Metastases in Neuroendocrine Tumors of the Appendix. <i>Annals of Surgery</i> , 2020, 271, 527-533.	2.1	44
2	Risk for Colorectal Adenomas Among Patients with Pancreatic Intraductal Papillary Mucinous Neoplasms: a Prospective Case- Control Study. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2020, 24, 445-450.	0.5	2
3	Searching for biomarkers in clinical practice: the prevalence and clinical significance of hypergammaglobulinemia in inflammatory bowel disease patients. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2020, 25, 565-568.	0.5	2
4	Genetic determinants of telomere length and risk of pancreatic cancer: A PANDoRA study. <i>International Journal of Cancer</i> , 2019, 144, 1275-1283.	2.3	36
5	Sunitinib in patients with pre-treated pancreatic neuroendocrine tumors: A real-world study. <i>Pancreatology</i> , 2018, 18, 198-203.	0.5	18
6	Therapy for Locoregional Disease: Stomach/Duodenum, Colon/Rectum. , 2018, , 219-234.		0
7	Recurrent biliary acute pancreatitis is frequent in a real-world setting. <i>Digestive and Liver Disease</i> , 2018, 50, 277-282.	0.4	16
8	Everolimus in advanced, progressive, well-differentiated, non-functional neuroendocrine tumors: <sc>RADIANT</sc> lung subgroup analysis. <i>Cancer Science</i> , 2018, 109, 174-181.	1.7	72
9	Clinical Usefulness of 18 F-fluorodeoxyglucose Positron Emission Tomography in the Diagnostic Algorithm of Advanced Entero-Pancreatic Neuroendocrine Neoplasms. <i>Oncologist</i> , 2018, 23, 186-192.	1.9	39
10	Mucosal adhesion and anti-inflammatory effects of <i>Lactobacillus rhamnosus</i> GG in the human colonic mucosa: A proof-of-concept study. <i>World Journal of Gastroenterology</i> , 2018, 24, 4652-4662.	1.4	43
11	Co-treatment with gemcitabine and nab-paclitaxel exerts additive effects on pancreatic cancer cell death. <i>Oncology Reports</i> , 2018, 39, 1984-1990.	1.2	10
12	Vitamins D and K as Factors Associated with Osteopathy in Chronic Pancreatitis: A Prospective Multicentre Study (P-BONE Study). <i>Clinical and Translational Gastroenterology</i> , 2018, 9, e197.	1.3	44
13	Heterogeneity of Duodenal Neuroendocrine Tumors: An Italian Multi-center Experience. <i>Annals of Surgical Oncology</i> , 2018, 25, 3200-3206.	0.7	39
14	Prevalence of chronic pancreatitis: Results of a primary care physician-based population study. <i>Digestive and Liver Disease</i> , 2017, 49, 535-539.	0.4	25
15	SLC22A3 polymorphisms do not modify pancreatic cancer risk, but may influence overall patient survival. <i>Scientific Reports</i> , 2017, 7, 43812.	1.6	15
16	Stage IV Gastro-Entero-Pancreatic Neuroendocrine Neoplasms: A Risk Score to Predict Clinical Outcome. <i>Oncologist</i> , 2017, 22, 409-415.	1.9	42
17	Active Surveillance Beyond 5 Years Is Required for Presumed Branch-Duct Intraductal Papillary Mucinous Neoplasms Undergoing Non-Operative Management. <i>American Journal of Gastroenterology</i> , 2017, 112, 1153-1161.	0.2	66
18	Risk and protective factors for the occurrence of sporadic pancreatic endocrine neoplasms. <i>Endocrine-Related Cancer</i> , 2017, 24, 405-414.	1.6	30

#	ARTICLE	IF	CITATIONS
19	Prognostic impact of the cumulative dose and dose intensity of everolimus in patients with pancreatic neuroendocrine tumors. <i>Cancer Medicine</i> , 2017, 6, 1493-1499.	1.3	11
20	Everolimus in Pancreatic Neuroendocrine Carcinomas G3. <i>Pancreas</i> , 2017, 46, 302-305.	0.5	53
21	Exclusive and Combined Use of Statins and Aspirin and the Risk of Pancreatic Cancer: a Case-Control Study. <i>Scientific Reports</i> , 2017, 7, 13024.	1.6	39
22	Health-related quality of life for everolimus versus placebo in patients with advanced, non-functional, well-differentiated gastrointestinal or lung neuroendocrine tumours (RADIANT-4): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2017, 18, 1411-1422.	5.1	74
23	The prevalence of pancreatic cystic lesions in patients with liver cirrhosis is double that in controls. <i>United European Gastroenterology Journal</i> , 2017, 5, 1007-1014.	1.6	8
24	Alternative polyadenylation of ZEB1 promotes its translation during genotoxic stress in pancreatic cancer cells. <i>Cell Death and Disease</i> , 2017, 8, e3168-e3168.	2.7	30
25	The Neutrophil/Lymphocyte Ratio at Diagnosis Is Significantly Associated with Survival in Metastatic Pancreatic Cancer Patients. <i>International Journal of Molecular Sciences</i> , 2017, 18, 730.	1.8	55
26	Hepatitis B in patients with hematological diseases: An update. <i>World Journal of Hepatology</i> , 2017, 9, 1043.	0.8	17
27	Sarcopenia Predicts Reduced Survival in Patients with Hepatocellular Carcinoma at First Diagnosis. <i>Annals of Hepatology</i> , 2017, 16, 107-114.	0.6	59
28	Impact of Ki67 re-assessment at time of disease progression in patients with pancreatic neuroendocrine neoplasms. <i>PLoS ONE</i> , 2017, 12, e0179445.	1.1	45
29	Antiproliferative effect of somatostatin analogs in advanced gastro-entero-pancreatic neuroendocrine tumors: a systematic review and meta-analysis. <i>Oncotarget</i> , 2017, 8, 46624-46634.	0.8	20
30	Gut microbiota and pancreatic diseases. <i>Minerva Gastroenterology</i> , 2017, 63, 399-410.	0.3	26
31	Endoscopy-guided ablation of pancreatic lesions: Technical possibilities and clinical outlook. <i>World Journal of Gastrointestinal Endoscopy</i> , 2017, 9, 41.	0.4	44
32	Common germline variants within the CDKN2A/2B region affect risk of pancreatic neuroendocrine tumors. <i>Scientific Reports</i> , 2016, 6, 39565.	1.6	15
33	Risk of pancreatic malignancy and mortality in branch-duct IPMNs undergoing surveillance: A systematic review and meta-analysis. <i>Digestive and Liver Disease</i> , 2016, 48, 473-479.	0.4	78
34	Statin Use and Survival in Resectable Pancreatic Cancer: Confounders and Mechanisms. <i>American Journal of Gastroenterology</i> , 2016, 111, 436.	0.2	1
35	Digestive neuroendocrine neoplasms: A 2016 overview. <i>Digestive and Liver Disease</i> , 2016, 48, 829-835.	0.4	14
36	Risk and Protective Factors for Small Intestine Neuroendocrine Tumors: A Prospective Case-Control Study. <i>Neuroendocrinology</i> , 2016, 103, 531-537.	1.2	28

#	ARTICLE	IF	CITATIONS
37	Endoscopic scores for inflammatory bowel disease in the era of "mucosal healing": Old problem, new perspectives. <i>Digestive and Liver Disease</i> , 2016, 48, 703-708.	0.4	20
38	Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study. <i>Lancet</i> , The, 2016, 387, 968-977.	6.3	962
39	Functional single nucleotide polymorphisms within the cyclin-dependent kinase inhibitor 2A/2B region affect pancreatic cancer risk. <i>Oncotarget</i> , 2016, 7, 57011-57020.	0.8	41
40	Molecular pathogenesis and targeted therapy of sporadic pancreatic neuroendocrine tumors. <i>Journal of Hepato-Biliary-Pancreatic Sciences</i> , 2015, 22, 594-601.	1.4	20
41	<i>TERT</i> gene harbors multiple variants associated with pancreatic cancer susceptibility. <i>International Journal of Cancer</i> , 2015, 137, 2175-2183.	2.3	57
42	Methods and outcomes of screening for pancreatic adenocarcinoma in high-risk individuals. <i>World Journal of Gastrointestinal Endoscopy</i> , 2015, 7, 833.	0.4	28
43	Exocrine Pancreatic Insufficiency in Diabetic Patients: Prevalence, Mechanisms, and Treatment. <i>International Journal of Endocrinology</i> , 2015, 2015, 1-7.	0.6	68
44	Early onset pancreatic cancer: Risk factors, presentation and outcome. <i>Pancreatology</i> , 2015, 15, 151-155.	0.5	60
45	Comparison of diffusion-weighted imaging and gadoxetic acid-enhanced MR images in the evaluation of hepatocellular carcinoma and hypovascular hepatocellular nodules. <i>Clinical Imaging</i> , 2015, 39, 468-475.	0.8	14
46	Critical Review of the Evidence on 5-Aminosalicylate for Chemoprevention of Colorectal Cancer in Ulcerative Colitis: A Methodological Question. <i>Current Clinical Pharmacology</i> , 2014, 9, 84-90.	0.2	7
47	Real-World Study of Everolimus in Advanced Progressive Neuroendocrine Tumors. <i>Oncologist</i> , 2014, 19, 966-974.	1.9	84
48	Advanced Digestive Neuroendocrine Tumors. <i>Pancreas</i> , 2014, 43, 212-218.	0.5	46
49	Radiolabelled somatostatin analogue treatment in gastroenteropancreatic neuroendocrine tumours: factors associated with response and suggestions for therapeutic sequence: response to comments by Ezziddin et al.. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 41, 176-177.	3.3	1
50	Diagnostic and therapeutic role of endoscopy in gastroenteropancreatic neuroendocrine neoplasms. <i>Digestive and Liver Disease</i> , 2014, 46, 9-17.	0.4	22
51	White Paper of Italian Gastroenterology: Delivery of services for digestive diseases in Italy: Weaknesses and strengths. <i>Digestive and Liver Disease</i> , 2014, 46, 579-589.	0.4	40
52	Combined therapy with RAD001 e BEZ235 overcomes resistance of PET immortalized cell lines to mTOR inhibition. <i>Oncotarget</i> , 2014, 5, 5381-5391.	0.8	41
53	"Mucosal healing" in ulcerative colitis: Between clinical evidence and market suggestion. <i>World Journal of Gastrointestinal Pathophysiology</i> , 2014, 5, 54.	0.5	7
54	Radiolabelled somatostatin analogue treatment in gastroenteropancreatic neuroendocrine tumours: factors associated with response and suggestions for therapeutic sequence. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2013, 40, 1197-1205.	3.3	50

#	ARTICLE	IF	CITATIONS
55	Molecular Pathogenesis of Neuroendocrine Tumors: Implications for Current and Future Therapeutic Approaches. <i>Clinical Cancer Research</i> , 2013, 19, 2842-2849.	3.2	80
56	Treatment of malignant pancreatic neuroendocrine neoplasms: middle-term (2-year) outcomes of a prospective observational multicentre study. <i>Hpb</i> , 2013, 15, 935-943.	0.1	16
57	Signalling Pathways Passing Src in Pancreatic Endocrine Tumours: Relevance for Possible Combined Targeted Therapies. <i>Neuroendocrinology</i> , 2013, 97, 67-73.	1.2	10
58	Novel Molecular Targets for the Treatment of Gastroenteropancreatic Endocrine Tumors: Answers and Unsolved Problems. <i>International Journal of Molecular Sciences</i> , 2013, 14, 30-45.	1.8	7
59	Molecular pathology and genetics of pancreatic endocrine tumours. <i>Journal of Molecular Endocrinology</i> , 2012, 49, R37-R50.	1.1	70
60	ENETS Consensus Guidelines for the Management of Patients with Gastroduodenal Neoplasms. <i>Neuroendocrinology</i> , 2012, 95, 74-87.	1.2	294
61	Risk Factors for Disease Progression in Advanced Jejunoileal Neuroendocrine Tumors. <i>Neuroendocrinology</i> , 2012, 96, 32-40.	1.2	55
62	Ki-67 grading of nonfunctioning pancreatic neuroendocrine tumors on histologic samples obtained by EUS-guided fine-needle tissue acquisition: a prospective study. <i>Gastrointestinal Endoscopy</i> , 2012, 76, 570-577.	0.5	158
63	Gastric and duodenal neuroendocrine tumours. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2012, 26, 719-735.	1.0	62
64	Promising Advances in the Treatment of Malignant Pancreatic Endocrine Tumors. <i>New England Journal of Medicine</i> , 2011, 364, 564-565.	13.9	53
65	Diagnosis and Management of Pernicious Anemia. <i>Current Gastroenterology Reports</i> , 2011, 13, 518-524.	1.1	57
66	Metastatic and Locally Advanced Pancreatic Endocrine Carcinomas: Analysis of Factors Associated With Disease Progression. <i>Journal of Clinical Oncology</i> , 2011, 29, 2372-2377.	0.8	261
67	Src kinase activity coordinates cell adhesion and spreading with activation of mammalian target of rapamycin in pancreatic endocrine tumour cells. <i>Endocrine-Related Cancer</i> , 2011, 18, 541-554.	1.6	32
68	Role of Resection of the Primary Pancreatic Neuroendocrine Tumour Only in Patients with Unresectable Metastatic Liver Disease: A Systematic Review. <i>Neuroendocrinology</i> , 2011, 93, 223-229.	1.2	103
69	Pancreatic Endocrine Tumors: Expression Profiling Evidences a Role for AKT-mTOR Pathway. <i>Journal of Clinical Oncology</i> , 2010, 28, 245-255.	0.8	497
70	Pancreatic endocrine tumors: improved TNM staging and histopathological grading permit a clinically efficient prognostic stratification of patients. <i>Modern Pathology</i> , 2010, 23, 824-833.	2.9	396
71	Clinicopathological Features of Pancreatic Endocrine Tumors: A Prospective Multicenter Study in Italy of 297 Sporadic Cases. <i>American Journal of Gastroenterology</i> , 2010, 105, 1421-1429.	0.2	125
72	Biological targeted therapies in patients with advanced enteropancreatic neuroendocrine carcinomas. <i>Cancer Treatment Reviews</i> , 2010, 36, S87-S94.	3.4	36

#	ARTICLE	IF	CITATIONS
73	Risk Factors for Sporadic Pancreatic Endocrine Tumors. American Journal of Gastroenterology, 2009, 104, 3034-3041.	0.2	52
74	Molecular target therapy for gastroenteropancreatic endocrine tumours: Biological rationale and clinical perspectives. Critical Reviews in Oncology/Hematology, 2009, 72, 110-124.	2.0	36
75	ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Biochemical Markers. Neuroendocrinology, 2009, 90, 194-202.	1.2	226
76	Occurrence and Risk Factors for Autoimmune Thyroid Disease in Patients with Atrophic Body Gastritis. American Journal of Medicine, 2008, 121, 136-141.	0.6	91
77	Gastroenteropancreatic neuroendocrine tumours. Lancet Oncology, The, 2008, 9, 61-72.	5.1	1,474
78	Src family kinase activity regulates adhesion, spreading and migration of pancreatic endocrine tumour cells. Endocrine-Related Cancer, 2007, 14, 111-124.	1.6	52
79	A Critical View of Molecularly Target Therapy for Digestive Endocrine Tumours. Recent Patents on Endocrine, Metabolic & Immune Drug Discovery, 2007, 1, 119-126.	0.7	0
80	Well-Differentiated Gastric Tumors/Carcinomas. Neuroendocrinology, 2006, 84, 158-164.	1.2	133
81	Thyroxine in Goiter, Helicobacter pylori Infection, and Chronic Gastritis. New England Journal of Medicine, 2006, 354, 1787-1795.	13.9	284
82	Endocrine tumours of the stomach. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2005, 19, 659-673.	1.0	72
83	Prognostic factors and survival in endocrine tumor patients: comparison between gastrointestinal and pancreatic localization. Endocrine-Related Cancer, 2005, 12, 1083-1092.	1.6	360
84	Gastric Neuroendocrine Tumors. Neuroendocrinology, 2004, 80, 16-19.	1.2	41
85	Atrophic body gastritis patients with enterochromaffin-like cell dysplasia are at increased risk for the development of type I gastric carcinoid. European Journal of Gastroenterology and Hepatology, 2001, 13, 1449-1456.	0.8	106
86	Inhibitory effect of somatostatin on neutral amino acid transport in isolated brain microvessels. Journal of Neurochemistry, 2001, 78, 349-357.	2.1	2
87	Sampling Strategies for Analysis of Enterochromaffin-like Cell Changes in Zollinger-Ellison Syndrome. American Journal of Clinical Pathology, 2000, 114, 419-425.	0.4	34
88	Quantitative ultrastructure of endocrine cells of oxyntic mucosa in Zollinger-Ellison syndrome. Gastroenterology, 1990, 99, 17-26.	0.6	79